Simulation of virtual patient populations for disease- and patient-specific drug development
CompanyCertara, Princeton, USA
The company Certara has developed the biosimulation software Symcyp to evaluate the pharmacokinetics of active ingredients to be tested. The platform can be used in all phases of drug development. It is useful for determining first-in-human dosage, optimizing clinical trial designs, evaluating new drug formulations, setting dose in untested populations, performing virtual bioequivalence analyses, and predicting drug-drug interactions (DDIs). To do this, Symcyp draws on an extensive set of genetic, physiological and epidemiological databases, which facilitates the simulation of virtual patient populations with different demographic characteristics, ethnicities and disease states. The multi-layered data sets and specially developed modules enable the modelling of (organ-)specific diseases, the investigation of various new routes of drug administration, and an assessment of extrinsic factors (such as the influence of smoking or alcohol consumption). In addition, the platform is suitable for drug prediction and dose determination for particularly vulnerable groups, such as infants, small children, pregnant women, breastfeeding mothers and older patients. In summary, the simulation software proves to be a valuable tool for accelerating and improving quantitative drug development and optimizing drug treatment strategies.
Simcyp™ PBPK Simulator
www.certara.com
Added on: 10-04-2023
[1] https://www.certara.com/software/simcyp-pbpk/
